The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of irinotecan plus bevacizumab for heavily pretreated recurrent ovarian cancer.
Salvia Sanjay Jain
No relevant relationships to disclose
Yan G. Makeyev
No relevant relationships to disclose
Franco Muggia
No relevant relationships to disclose
James L. Speyer
No relevant relationships to disclose
John Patrick Curtin
No relevant relationships to disclose
Stephanie V. Blank
No relevant relationships to disclose
Leslie R. Boyd
No relevant relationships to disclose
Bhavana Pothuri
No relevant relationships to disclose
David Fishman
No relevant relationships to disclose
Xiaochun Li
No relevant relationships to disclose
Judith D. Goldberg
No relevant relationships to disclose
Amy Tiersten
No relevant relationships to disclose